What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-08-16 compared with 2021-06-24 · 32 added, 47 removed, 26 unchanged (75% of the section changed)

Other Information

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrants Current

Report on Form 8-K, filed with the SEC on May 18, 2021).

Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 18, 2021).

Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 18, 2021).

Form of Class

A Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrants Registration Statement on Form S-1, as amended (File No.

Form of Class A Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Second Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated October 29,

2020 (incorporated by reference to Exhibit 4.2 to the Registrants Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on

April 23, 2021).

Second Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated October 29, 2020 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on April 23, 2021).

Vera Therapeutics, Inc.

2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrants Registration Statement

on Form S-1, as amended (File No.

2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc.

2021 Equity Incentive Plan

(incorporated by reference to Exhibit 10.4 to the Registrants Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on

May 10, 2021).

2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Vera Therapeutics, Inc.

2021 Equity Incentive Plan (incorporated by

reference to Exhibit 10.5 to the Registrants Registration Statement on Form S-1, as amended (File No.

2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Vera Therapeutics, Inc.

2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrants Registration Statement

on Form S-1, as amended (File No.

2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Vera Therapeutics, Inc.

2021 Non-Employee Director Compensation Policy (incorporated by reference to Exhibit

10.7 to the Registrants Registration Statement on Form S-1, as amended (File No.

2021 Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Amended and Restated Offer Letter by and between the Registrant and Marshall Fordyce, M.D., dated May

7, 2021 (incorporated by reference to Exhibit 10.9 to the Registrants Registration Statement on Form S-1, as amended (File No.

Amended and Restated Offer Letter by and between the Registrant and Marshall Fordyce, M.D., dated May 7, 2021 (incorporated by reference to Exhibit 10.9 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Amended and Restated Offer Letter by and between the Registrant and Joanne Curley, Ph.D., dated May

7, 2021 (incorporated by reference to Exhibit 10.10 to the Registrants Registration Statement on Form S-1, as amended (File No.

Amended and Restated Offer Letter by and between the Registrant and Joanne Curley, Ph.D., dated May 7, 2021 (incorporated by reference to Exhibit 10.10 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Amended and Restated Offer Letter by and between the Registrant and Celia Lin, M.D., dated May

7, 2021 (incorporated by reference to Exhibit 10.14 to the Registrants Registration Statement on Form S-1, as amended (File No.

Amended and Restated Offer Letter by and between the Registrant and Celia Lin, M.D., dated May 7, 2021 (incorporated by reference to Exhibit 10.14 to the Registrant’s Registration Statement on Form S-1, as amended (File No.

333-255492), filed with the SEC on May 10, 2021).

Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934,

as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934,

as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Offer Letter by and between the Registrant and Sean P.

Grant, dated May 30, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 14, 2021).

Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Executive Officer pursuant to 18 U.S.C.

2 unchanged sentences

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

XBRL Instance Document

XBRL Taxonomy Extension Schema Document

XBRL Taxonomy Extension Calculation Linkbase Document

XBRL Taxonomy Extension Definition Linkbase Document

XBRL Taxonomy Extension Label Linkbase Document

XBRL Taxonomy Extension Presentation Linkbase Document

Inline XBRL Instance Document

Inline XBRL Taxonomy Extension Schema Document

Inline XBRL Taxonomy Extension Calculation Linkbase Document

Inline XBRL Taxonomy Extension Definition Linkbase Document

Inline XBRL Taxonomy Extension Label Linkbase Document

Inline XBRL Taxonomy Extension Presentation Linkbase Document

Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

Filed herewith.

Indicates management contract or compensatory plan.

The information in Exhibits 32.1 and 32.2 shall not be deemed filed for purposes of Section 18

of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act

of 1934, as amended (including this Quarterly Report on Form 10-Q), unless the Registrant specifically incorporates the foregoing information into those documents by reference.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned

thereunto duly authorized.

The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (including this Quarterly Report on Form 10-Q),

unless the Registrant specifically incorporates the foregoing information into those documents by reference.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Vera Therapeutics, Inc.

June 24, 2021

August 16, 2021

/s/ Marshall Fordyce

1 unchanged sentence

Chief Executive Officer

(Principal Executive

June 24, 2021

/s/ Jonathan Wolter

Jonathan Wolter

(Principal Executive Officer)

August 16, 2021

/s/ Sean Grant

Chief Financial Officer

(Principal Financial

(Principal Financial Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information